PubRank

Felix J M van der Meer

Author PubWeight™ 42.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013 4.27
2 Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med 2009 2.16
3 A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. Am J Clin Pathol 2006 2.09
4 Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005 2.06
5 Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004 2.00
6 Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol 2010 1.55
7 Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol 2008 1.49
8 A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thromb Haemost 2009 1.46
9 Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost 2009 1.46
10 Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. Clin Chem 2006 1.40
11 Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005 1.12
12 Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011 1.07
13 The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009 1.04
14 Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol 2003 0.98
15 Using the common-sense model to predict risk perception and disease-related worry in individuals at increased risk for venous thrombosis. Health Psychol 2007 0.95
16 Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002 0.95
17 Interpretation and management of INR results: a case history based survey in 13 countries. Thromb Res 2012 0.88
18 Long-term stability of frozen pooled plasmas stored at -70°C, -40°C, and -20°C for prothrombin time and International Normalized Ratio (INR) assessment. Thromb Res 2013 0.87
19 Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003 0.85
20 The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon. Br J Clin Pharmacol 2012 0.84
21 Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug Metabol Drug Interact 2012 0.82
22 The influence of exogenous magnesium chloride on the apparent INR determined with human, rabbit, and bovine thromboplastin reagents. Thromb Haemost 2003 0.81
23 The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon. Thromb Res 2008 0.80
24 Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands. Br J Haematol 2012 0.80
25 A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage. Br J Haematol 2008 0.79
26 Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005 0.79
27 Point-of-care monitoring of vitamin K-antagonists: validation of CoaguChek XS test strips with International Standard thromboplastin. J Clin Pathol 2012 0.78
28 Influence of haematocrit on international normalised ratio (INR) differences between a whole blood point-of-care coagulation monitor and reference prothrombin time in plasma. Thromb Haemost 2008 0.78
29 Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica 2010 0.77
30 The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A. Thromb Haemost 2015 0.77
31 Influence of blood collection systems on the prothrombin time and international sensitivity index determined with human and rabbit thromboplastin reagents. Am J Clin Pathol 2007 0.77
32 Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden. Thromb Res 2007 0.77
33 Quality control of CoaguChek test strips in the Netherlands. Thromb Haemost 2007 0.76
34 Statins and Risk of Bleeding: An Analysis to Evaluate Possible Bias Due to Prevalent Users and Healthy User Aspects. Am J Epidemiol 2016 0.76
35 Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med 2003 0.75
36 External quality assessment (EQA) for CoaguChek monitors. Thromb Haemost 2010 0.75
37 Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics 2012 0.75
38 Phenprocoumon and acenocoumarol treatment in paediatric patients. Thromb Haemost 2012 0.75
39 Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation. Thromb Haemost 2016 0.75
40 Control of anticoagulation with VKAs: overestimation of median TTR when assessed by linear interpolation: Reply. Thromb Haemost 2017 0.75
41 Comparative study of blood collection tubes and thromboplastin reagents for correction of INR discrepancies: a proposal for maximum allowable magnesium contamination in sodium citrate anticoagulant solutions. Am J Clin Pathol 2012 0.75